These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 32060897)

  • 1. Overview of treatment approaches to osteoporosis.
    Langdahl BL
    Br J Pharmacol; 2021 May; 178(9):1891-1906. PubMed ID: 32060897
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of postmenopausal osteoporosis with bone-forming and antiresorptive treatments: Combined and sequential approaches.
    Langdahl B
    Bone; 2020 Oct; 139():115516. PubMed ID: 32622871
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current Status of Bone-Forming Therapies for the Management of Osteoporosis.
    Sølling ASK; Harsløf T; Langdahl B
    Drugs Aging; 2019 Jul; 36(7):625-638. PubMed ID: 31066015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New anti-resorptives and antibody mediated anti-resorptive therapy.
    Farrier AJ; Sanchez Franco LC; Shoaib A; Gulati V; Johnson N; Uzoigwe CE; Choudhury MZ
    Bone Joint J; 2016 Feb; 98-B(2):160-5. PubMed ID: 26850419
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-resorptives in the management of osteoporosis.
    Miller PD
    Best Pract Res Clin Endocrinol Metab; 2008 Oct; 22(5):849-68. PubMed ID: 19028360
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New therapeutic targets for osteoporosis.
    Anagnostis P; Gkekas NK; Potoupnis M; Kenanidis E; Tsiridis E; Goulis DG
    Maturitas; 2019 Feb; 120():1-6. PubMed ID: 30583758
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The relative merits of anabolics versus anti-resorptive compounds: where our targets should be, and whether we are addressing them.
    Gasser JA
    Curr Opin Pharmacol; 2006 Jun; 6(3):313-8. PubMed ID: 16650802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current and emerging osteoporosis pharmacotherapy for women: state of the art therapies for preventing bone loss.
    Fontalis A; Kenanidis E; Kotronias RA; Papachristou A; Anagnostis P; Potoupnis M; Tsiridis E
    Expert Opin Pharmacother; 2019 Jun; 20(9):1123-1134. PubMed ID: 30958709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Osteoporosis, bone mineral density and CKD-MBD: treatment considerations.
    Bover J; Bailone L; López-Báez V; Benito S; Ciceri P; Galassi A; Cozzolino M
    J Nephrol; 2017 Oct; 30(5):677-687. PubMed ID: 28432640
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Using Osteoporosis Therapies in Combination.
    McClung MR
    Curr Osteoporos Rep; 2017 Aug; 15(4):343-352. PubMed ID: 28667435
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of postmenopausal osteoporosis and the prevention of fractures.
    Gambacciani M; Levancini M
    Panminerva Med; 2014 Jun; 56(2):115-31. PubMed ID: 24942322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacology of bisphosphonates in pain.
    Tzschentke TM
    Br J Pharmacol; 2021 May; 178(9):1973-1994. PubMed ID: 31347149
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-resorptive therapy for the prevention of postmenopausal osteoporosis : when should treatment begin?
    Vestergaard P
    Treat Endocrinol; 2005; 4(5):263-77. PubMed ID: 16185096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Duration of anti-resorptive therapy for osteoporosis.
    Adler RA
    Endocrine; 2016 Feb; 51(2):222-4. PubMed ID: 26433739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-resorptive therapies for osteoporosis.
    Reid IR
    Semin Cell Dev Biol; 2008 Oct; 19(5):473-8. PubMed ID: 18760372
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of Denosumab Therapy Following Treatment with Bisphosphonates in Women with Osteoporosis: A Cohort Study.
    Marocco C; Zimatore G; Mocini E; Fornari R; Iolascon G; Gallotta MC; Bimonte VM; Baldari C; Lenzi A; Migliaccio S
    Int J Environ Res Public Health; 2021 Feb; 18(4):. PubMed ID: 33579002
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MANAGEMENT OF ENDOCRINE DISEASE: Atypical femoral fractures: risks and benefits of long-term treatment of osteoporosis with anti-resorptive therapy.
    Adler RA
    Eur J Endocrinol; 2018 Mar; 178(3):R81-R87. PubMed ID: 29339529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic targets in myeloma bone disease.
    Marino S; Petrusca DN; Roodman GD
    Br J Pharmacol; 2021 May; 178(9):1907-1922. PubMed ID: 31647573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Good and the Bad About the 2017 American College of Physicians Osteoporosis Guidelines.
    Lagari V; Gavcovich T; Levis S
    Clin Ther; 2018 Jan; 40(1):168-176. PubMed ID: 29196083
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of osteoporosis medications on bone quality.
    Benhamou CL
    Joint Bone Spine; 2007 Jan; 74(1):39-47. PubMed ID: 17196423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.